Covidh Technologies Becomes iSERA Lifesciences, Appoints Four Directors

Covidh Technologies Limited convened its Extra-Ordinary General Meeting (EGM) on April 2, 2026, via video conferencing. Shareholders demonstrated strong support, approving all five resolutions.

EGM Approves Key Changes

A key special resolution formally changed the company's name from "Covidh Technologies Limited" to "iSERA Lifesciences Limited." This move reflects the company's strategic future in the life sciences sector.

Ordinary resolutions also successfully appointed four new directors to the board: Mr. Dhairyasheel Vasantrao Yadav, Mr. Nandkumar Subhash Kadam, Mr. Pratap Dadasaheb Deshmukh, and Ms. Ritu Dhanraj Garad. These appointments are expected to strengthen the company's leadership.

Strategic Pivot to Life Sciences

The EGM outcome marks a major strategic shift for Covidh Technologies. The transition to "iSERA Lifesciences Limited" signals a move from its historical IT/ITES and software services business into the biotechnology and pharmaceutical domain.

This name change is directly linked to the company's prior intention to acquire iSERA Biological Private Limited, an entity focused on biopharmaceuticals. The new board appointments, including Mr. Pratap Dadasaheb Deshmukh who also serves as a director at iSERA Biological, will guide this new direction.

From IT to Life Sciences

Originally established in 1993 as a software and IT services firm, Covidh Technologies had previously outlined plans for expansion. A non-binding Letter of Intent was signed to acquire iSERA Biological Private Limited, a company focused on the life sciences sector. This acquisition appears to have prompted the name change and board restructuring.

Key Changes and New Direction

The company is now formally shifting its business focus towards the life sciences and biotechnology sector.
The new name, "iSERA Lifesciences Limited," will better reflect its future operations and market positioning.
The induction of four new directors, some with direct ties to iSERA Biological, brings expertise vital for life sciences.
This move could attract investors interested in the pharmaceutical and biotech growth story.

Transition Risks Ahead

While EGM resolutions passed smoothly, transitioning into the highly regulated life sciences sector presents execution risks. Successfully integrating operations and new director expertise will be crucial.

Competitors in the Life Sciences Sector

As iSERA Lifesciences Limited, the company will now operate in the competitive Indian pharmaceutical and biotechnology landscape. Key players include: Sun Pharmaceutical Industries Ltd., Divi's Laboratories Ltd., Cipla Ltd., and Dr. Reddy's Laboratories Ltd. The Indian pharmaceutical market is a major global player with significant growth projected.

Data Snapshot

The EGM saw 1,052 shareholders participate, representing 18.25% of outstanding shares.

What Investors Should Watch

• Official announcement of the company's name change to iSERA Lifesciences Limited.
• Details on the completion and integration of the iSERA Biological Private Limited acquisition.
• The new strategy and business plan under the new identity.
• Performance of new directors in guiding growth in the life sciences sector.
• Future announcements regarding product development, R&D, or market expansion in pharmaceuticals and biotech.